Improving Biopharma R&D Lifecycle Management with Biopharma 4.0
Report
As the Covid-19 pandemic puts a renewed focus on the time and cost of bringing new therapeutics and vaccines to market, this report explores why implementing a biopharma 4.0 approach is necessary for achieving higher flexibility, efficiency and robustness in the lifecycle of a drug.
Key points:
- Why industry leaders believe biopharma 4.0 provides them with an end-to-end solution market advantage in R&D
- Which solutions can help you navigate the challenges of data management during drug development
- How to navigate the biopharma lifecycle using IDBS’ Polar biopharma life cycle management platform
More whitepapers
Navigating your digital journey to AI success
The first critical step in your digital journey, before implementing AI, is to ensure you’re at the right level of…
Mitigating risks to quality, continuity and talent retention through digital transformation
Drug sponsors and CROs must have a symbiotic relationship. Yet sponsors feel underserved by these partnerships. Is talent retention to…
Using Software Systems to Drive a Successful CPV Program
Want smarter manufacturing data management? The key is using software systems to drive a successful CPV program. This paper will…
BioProcess International: Cell and Gene Therapy Data Management
At the Phacilitate Leaders World and World Stem Cell Summit 2019, held 22-25 Jan, Steve Goodman (Head of Drug Product…